Guía de práctica clínica: tocilizumab para pacientes con COVID-19 grave o crítica / Clinical practice guideline: tocilizumab for patients with severe and critical COVID-19

Resumen En COVID-19, existen estados de hiperinflamación, donde la inmunosupresión y bloqueo de receptores de IL-6 podría ser beneficiosa. Se desarrolló una guía de práctica clínica con apoyo del gru po metodológico, utilizando el método GRADE (Grading of Recommendations Assessment, Development and Evaluation) acerca del uso de tocilizumab para pacientes con COVID-19 grave y crítica. Siguiendo métodos de elaboración de guías de la OMS, se conformó un grupo multidisciplinario compuesto por expertos temáticos clí nicos y en políticas públicas, metodólogos y usuarios. Todos lo s participantes del panel y del grupo desarrollador firmaron una declaración de conflicto de interés. Se realizaron búsquedas de estudios aleatorizados hasta el 17 de abril de 2021, en la base de datos L.OVE de la fundación Epistemonikos. Se elaboró la síntesis y los perfiles de evidencia utilizando el enfoque GRADE y se desarrolló un modelo para valorar el impacto presupuestario de la incorporación de tociliuzmab. Posteriormente, la recomendación fue graduada en un panel de expertos temáti cos. Se sugiere utilizar tocilizumab en hospitalizados con COVID-19 grave y crítica. Recomendación condicional, certeza en la evidencia moderada. Consideraciones para la implementación. A. Dosis: 8 mg/kg de peso real, única dosis, por vía endovenosa, dosis máxima 800 mg; B. Administrar dexametasona 8 mg (o equivalente) por 10 días conjuntamente con tocilizumab; C. La recomendación aplica a: 1. pacientes con enfermedad grave definida como SpO2 ≤ 92% con aire ambiente y/o pacientes que reciben oxígeno suplementario (incluyendo cánula nasal de alto flujo y ventilación no invasiva); 2. pacientes con enfermedad crítica (ventilación mecánica invasiva).

Abstract In COVID-19, there are states of hyperinflammation in severely or critically ill people, where immu nosuppression and blocking of IL-6 receptors could be beneficial. Faced with this situation, with the support of a methods group using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach, about the use of tocilizumab for patients with severe and critical illness coronavirus. This guide fo cuses on making recommendations for the use of tocilizumab in patients with severe and critical COVID-19. This clinical practice guideline was prepared following the WHO guideline development methods. A multidisciplinary development group was formed, with clinical and health policy experts, methodologists and users. Panel and methods group members signed a declaration of conflict of interest. We searched the Epistemonikos Founda tion's L.OVE database for randomized studies up to April 17, 2021. The synthesis and evidence profiles were prepared using the GRADE approach and an economic model was developed. Among hospitalized adults with progressive severe or critical COVID-19, the guideline panel su ggests tocilizumab. (Conditional recommendation, Moderate certainty of evidence) Implementation considerations. A. Dose: 8 mg/kg of actual weight, single-dose, intravenously), maximum dose 800 mg; B. Administer dexamethasone 8 mg (or equivalent) for 10 days together with tocilizumab; C. The recommendation applies to: 1. patients with severe disease defined as SpO2 ≤ 92% with room air and/or patients receiving supplemental oxygen (including a high-flow nasal cannula and non-invasive ventilation); 2. critically ill patients: requiring invasive mechanical ventilation.

Development of simple and sensitive score to assess the risk of pneumonia in Covid-19 patients

ABSTRACT Background: Severe pneumonia is the most common cause of intensive care unit (ICU) admission and death due to novel coronavirus (SARS-CoV-2) respiratory disease (COVID-19). Due to its rapid outbreak, units for the evaluation of febrile patients in the pre-hospital setting were created. Objective: The objective of the study was to develop a sensitive and simple tool to assess the risk of pneumonia in COVID-19 patients and thus select which patients would require a chest imaging study. Materials and Methods: We conducted a cross-sectional study in a cohort of individuals with suspected COVID-19 evaluated in a public academic healthcare center in Buenos Aires city. All adult patients with positive RT-PCR assay for SARS-COV2 between April 24 and May 19 of 2020 were included in the study. Pneumonia was defined as the presence of compatible signs and symptoms with imaging confirmation. Univariate and multivariate logistic regression was performed. A risk indicator score was developed. Results: One hundred and forty-eight patients were included, 71 (48%) received the diagnosis of pneumonia. The final clinical model included four variables: age ≥ 40 years, cough, absence of sore throat, and respiratory rate ≥ 22. To create the score, we assigned values to the variables according to their ORs: 2 points for respiratory rate ≥ 22 and 1 point to the other variables. The AUC of the ROC curve was 0.80 (CI 95% 0.73-0.86). A cutoff value of 2 showed a sensitivity of 95.7% and a specificity of 43.24%. Conclusion: This sensible score may improve the risk stratification of COVID-19 patients in the pre-hospital setting. (REV INVEST CLIN. 2021;73(1):52-8)